Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Perrigo

This page shows the latest Perrigo news and features for those working in and with pharma, biotech and healthcare.

As CEO returns, Valeant admits SEC probe

As CEO returns, Valeant admits SEC probe

A lower-cost generic version from Perrigo "outsells the branded product by more than 250 to 1", it added.

Latest news

  • Mylan agrees to buy Sweden's Meda for $7.2bn Mylan agrees to buy Sweden's Meda for $7.2bn

    Mylan has shrugged off the disappointment of its failed bid for Perrigo with a $7.2bn deal to merge with Swedish pharma company Meda. ... albeit not as large as would have been forthcoming with the proposed $26bn Perrigo deal.

  • Mylan buys into six biosimilars, including Orencia candidate Mylan buys into six biosimilars, including Orencia candidate

    To bolster its portfolio and pipeline, Mylan mounted a hostile takeover for generic and over-the-counter (OTC) drug specialist Perrigo last year, but failed to bring the deal to a

  • AstraZeneca sets sights on China with Takeda deal AstraZeneca sets sights on China with Takeda deal

    The company also recently sold off US rights to gastroenterology drug Entocort (budesonide) to Perrigo for $380m, saying the product lay outside its strategic focus.

  • Mylan misses Perrigo takeover deadline Mylan misses Perrigo takeover deadline

    Mylan misses Perrigo takeover deadline. Failureto take 50% stake ends near-term hopes for a bid. ... Shares in Mylan ended the day on Friday up 13%, while Perrigo fell around 6%.

  • Teva planning fresh offer for Mylan, say sources Teva planning fresh offer for Mylan, say sources

    Under chairman Robert Coury, Mylan has rebuffed all of Teva's attempts to get around the negotiating table whilst pursuing its own acquisition of an equally reluctant Perrigo, based in Ireland, ... There have been some s ignals of late however that

More from news
Approximately 9 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Pharma deals continue to slide Pharma deals continue to slide

    $35bn. $7.3bn. Valeant. 40. 17.5. -56%. $28bn. ($2.4bn). Perrigo. 90. 78. ... Perrigo, like Teva and Valeant, is seeking to reduce debt. Biotech companies are also selling (or licensing) assets to stay alive.

  • Deal Watch February 2017 Deal Watch February 2017

    The largest of these was Perrigo's divestment to Royalty Pharma of its royalty stream from Biogen's global sales of Tysabri (natalizumab), the multiple sclerosis antibody originally developed by Elan, ... 17, 900. Perrigo/ Royalty Pharma. Tysabri

  • Deal Watch August 2016 Deal Watch August 2016

    In contrast, in 2015 Mylan made a tender offer for Perrigo. ... Sep 15 / Hostile. Mylan. Perrigo. $26bn. Tender offer failed as Mylan shares dropped in value (Teva withdrew bid).

  • Deal Watch November 2015 Deal Watch November 2015

    Perrigo paid a multiple of 3.2x sales for the US rights whereas Tillotts paid 4.1x sales. ... 386. AstraZeneca. Perrigo. Acquisition - asset. Entocort (budesonide) marketed for mild to moderate Crohn's disease.

  • Pharma deals in August 2015 Pharma deals in August 2015

    Hostile takeovers remained a topic of conversation this month as the Perrigo / Mylan saga played on; the vote taken by Mylan's shareholders on 28 August indicated support for the deal ... Perrigo had previously expressed concerns over Mylan's corporate

More from intelligence
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest appointments

  • Perrigo appoints Gerresheimer’s Uwe Rohrhoff as CEO Perrigo appoints Gerresheimer’s Uwe Rohrhoff as CEO

    Perrigo appoints Gerresheimer’ s Uwe Rohrhoff as CEO. He succeeds John Hendrickson, who resigns as CEO and board member. ... Generic pharmaceutical company Perrigo has appointed Uwe Rohrhoff, Gerresheimer’s former chief executive officer, as its new

  • BMS appoints three independent directors BMS appoints three independent directors

    He currently serves as a director at Perrigo Company and Stamps.com, and is the former president of Capital Guardian Trust Company, and global equity portfolio manager at Capital Group.

  • Valeant appoints Joseph Papa to end CEO uncertainty Valeant appoints Joseph Papa to end CEO uncertainty

    Valeant's month-long search for a new chief executive has ended with its selection of Perrigo's Joseph Papa to replace current CEO Michael Pearson in early May. ... He moves to Valeant from his most recent role as chief executive officer and chairman of

  • Perrigo promotes Neil Lister to UK leadership role Perrigo promotes Neil Lister to UK leadership role

    Perrigo promotes Neil Lister to UK leadership role. He will head up the firm's UK and Ireland business. ... Dublin-based Perrigo Company, has promoted Neil Lister to lead its newly-combined UK and Ireland business.

  • Keith Webber leaves FDA for Perrigo Keith Webber leaves FDA for Perrigo

    Perrigo Company has named former US Food and Drug Administration (FDA) employee Keith Webber as head of its regulatory review process. ... The role marks a switch to the industry side of pharma for Webber, heading all the Perrigo's regulatory activities

More from appointments
Approximately 3 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
McCann Complete Medical

Complete Medical delivers world-class solutions in medical communications, regulatory services, healthcare multichannel excellence, and strategic consultancy. We bring together specialist...

Latest intelligence

Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...
Light_bulb_Stock_Market.jpg
Creativity has lost its worth
Creativity has lost its worth, and sadly it is undermining effectiveness...

Quick links

Infographics

Multimedia